Michael Howe - Aspire BioPharma CEO Director

ASBP Stock   0.06  0.02  26.44%   

CEO

Michael Howe is CEO Director of Aspire BioPharma
Age 72
Address 23150 Fashion Drive, Estero, FL, United States, 33928
Phone415 592 7399
Webhttps://aspirebiolabs.com

Aspire BioPharma Management Efficiency

The company has return on total asset (ROA) of (1.9511) % which means that it has lost $1.9511 on every $100 spent on assets. This is way below average. Aspire BioPharma's management efficiency ratios could be used to measure how well Aspire BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/15/2026, Return On Equity is likely to grow to 17.05, though Return On Tangible Assets are likely to grow to (92.55). As of 01/15/2026, Total Current Liabilities is likely to grow to about 2 M, while Liabilities And Stockholders Equity is likely to drop slightly above 126.5 K.

Similar Executives

Found 5 records

CEO Age

Sabrina JohnsonDare Bioscience
59
William MDBriacell Therapeutics Corp
70
J FinleyPalisade Bio
69
Myron HolubiakCitius Pharmaceuticals
79
MD FCPABriacell Therapeutics Corp
71
Aspire BioPharma (ASBP) is traded on NASDAQ Exchange in USA and employs 4 people. Aspire BioPharma was previously known as PWUP Old and was traded on NASDAQ Exchange under the symbol PWUP. Aspire BioPharma is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Aspire BioPharma Leadership Team

Elected by the shareholders, the Aspire BioPharma's board of directors comprises two types of representatives: Aspire BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aspire. The board's role is to monitor Aspire BioPharma's management team and ensure that shareholders' interests are well served. Aspire BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aspire BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stephen Quesenberry, Corporate Counsel
Michael Howe, CEO Director
Ernest Scheidemann, Chief Officer
Kraig Higginson, President Board

Aspire Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aspire BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Aspire BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aspire BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aspire BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Aspire Stock

  0.9AZN AstraZeneca PLC ADRPairCorr
  0.82PFE Pfizer IncPairCorr
  0.8JNJ Johnson Johnson Earnings Call This WeekPairCorr
  0.8VWAGY Volkswagen AG 110PairCorr
  0.79VLKAF Volkswagen AGPairCorr
The ability to find closely correlated positions to Aspire BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aspire BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aspire BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aspire BioPharma to buy it.
The correlation of Aspire BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aspire BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aspire BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aspire BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Aspire Stock Analysis

When running Aspire BioPharma's price analysis, check to measure Aspire BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma is operating at the current time. Most of Aspire BioPharma's value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma's price. Additionally, you may evaluate how the addition of Aspire BioPharma to your portfolios can decrease your overall portfolio volatility.